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ABSTRACT 
 
Lactate Dehydrogenase (LDH) catalyzes the interconversion of pyruvate and lactate in the 
final step of anaerobic glycolysis. Many invasive tumors depend on an increased rate of glycolysis in 
order to maximize their growth potential under hypoxic environments, a phenomenon known as the 
“Warburg Effect.” By finding a way to inhibit LDH, contributions would be made towards the 
management of cancerous cells by inhibition of their energy production. 
Human LDH isoenzyme A was subcloned into an in-house vector (pET28a with a 
PreScission cleavage site) and overexpressed in E. coli Tuner(DE3) cells as a fusion protein with 
maltose binding protein (MBP) to increase solubility. The fusion protein was cleaved, purified, and 
subjected to crystallization trials using the hanging drop vapor diffusion method. 
Crystals of the binary complex of LDH-A with NADH were obtained, and conditions 
continue to be optimized in order to increase crystal size and diffraction quality. Steady-state kinetic 
characterization revealed Km(Pyruvate) to be 130 ± 19 µM and the specific activity to be 382 ± 16 U/mg. 
The IC50 value for the known weak inhibitor oxamate was determined to be 65 ± 2 µM. 
Future plans include high-throughput screening (HTS) for novel LDH-A inhibitors, co-
crystallization of LDH-A with HTS hit compounds, and the structure-based design of potent and 
specific inhibitors of this enzyme. 
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1 INTRODUCTION 
1.1 Background of  Lactate Dehydrogenase 
Lactate Dehydrogenase (LDH) is a glycolytic enzyme that catalyzes the conversion of 
pyruvate and NADH to lactic acid and NAD+, or vice versa (Figure 1). The purpose of this pathway 
is to regenerate NAD+, which can be reduced to NADH in the early steps of glycolysis. This 
pathway is important for generating ATP in the absence of oxygen, and is a primary source of 
NAD+ for anaerobic cells that rely on fermentation for energy. 
 
 
Figure 1. Enzymatic reaction of lactate dehydrogenase 
In most eukaryotic cells, the primary source of ATP is oxidative phosphorylation, which 
requires oxygen; therefore, the previously mentioned pathway can be utilized when oxygen becomes 
less abundant, such as during strenuous physical activity. Cancer cells tend to opt for this glycolytic 
pathway in order to maximize their growth potential even in the presence of oxygen. This is known 
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as the “Warburg effect.” The main reason this occurs is that, as cells become cancerous, 
mitochondrial function ceases, triggering apoptosis in an effort to kill the cell. For cancer cells this 
means that there must be another mechanism for obtaining energy to continue metabolism (4). 
Finding a means to inhibit LDH would contribute significantly towards the management of 
cancerous cells by inhibiting their energy production mechanism. LDH is expressed from three 
different genes: ldha, ldhb, and ldhc. These genes are transcribed and translated to form the protein 
subunits M, H, and the testis specific subunit, respectively. Upon translation, these subunits form a 
tetramer which constitutes an active LDH enzyme. Various tissue types express different isoforms 
of LDH-A, as the subunits arrange in different combinations. LDH-A (with four M subunits made 
by the LDH-A gene) is most abundant in skeletal muscle, where glycolysis is required to meet 
metabolic needs when oxygen is low during strenuous physical activity. LDH-B is most abundant in 
cardiac muscle, and is used to continue energy production when oxygen levels decrease. LDH-C is 
an isoform that is present in the testes and is required for spermatogenesis and sperm function. 
Targeted disruption of LDH-C impairs fertility in male mice and was once considered specific to 
male germs cells only (2). More recently, LDH-C was also found in tumors such as lung cancer, 
melanoma, breast cancer, and prostate cancer (2). 
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2 MATERIALS AND METHODS 
• Water from a Barnstead NANOpure Diamond purifying device from Thermo Scientific was 
used for all applications. 
2.1 Solutions and Media 
2.1.1 Antibiotic stock solutions 
Kanamycin (Kan): Ampicillin (Amp): 
30 mg/mL Kanamycin 100 mg/mL Ampicillin 
Antibiotic stocks were purified using a 0.4 μm filter and were diluted 1:1000 when used.   
2.1.2 Solutions for protein purification 
Buffer A – NiNTA #1: Buffer B – NiNTA #1 : Desalting Buffer #1: 
100 mM Na/K Phosphate 100 mM Na/K Phosphate  100 mM Na/K Phosphate 
300 mM NaCl 300 mM NaCl 150 mM NaCl 
20 mM Imidazole 250 mM Imidazole 1 mM DTT 
pH 7.5 pH 7.5 pH 6.8 
Buffer A – NiNTA #2: Buffer B – NiNTA #2: Buffer A – Q Sepharose:
100 mM Na/K Phosphate 100 mM Na/K Phosphate 50 mM Tris 
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300 mM NaCl 300 mM NaCl 1 mM EDTA 
25 mM Imidazole 250 mM Imidazole 1 mM DTT 
pH 6.8 pH 6.8 pH 7.5 
Buffer B – Q Sepharose: Gel Filtration Buffer: Crystallization Buffer: 
50 mM Tris 100 mM Phosphate 50 mM Tris 
1 mM EDTA 150 mM NaCl 2 mM DTT 
1 mM DTT 1 mM DTT pH 8.0 
400 mM KCl pH 6.8 
pH 7.5 
ÆFPLC solutions were made using deionized water cooled to 4 °C.  Following filtration 
with a 0.45 μm filter, the pH was adjusted with 12 N HCl /1 N NaOH at 4 °C.   
2.1.3 Growth media 
2X YT broth (1L): TB (900mL): LB broth (1L): LB-Agar(0.5L): 
16 g tryptone 12 g tryptone 10 g tryptone  5 g (s) NaCl 
10 g yeast extract 24 g yeast extract 5 g yeast extract 5 g tryptone 
5 g NaCl 4 mL 100% glycerol 5 g NaCl  2.5 g yeast 
     10 g agar 
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     500 mL water 
Luria-Bertani (LB), 2x YT, and TB broths were prepared by combining the above components 
and autoclaving the solution. Filter-purified antibiotic stocks were added prior to use, and unused 
media was stored at 4 °C. 
LB-Agar was prepared by mixing the components, then autoclaving the mixture to ensure 
sterility and dissolve the agar. The agar was allowed to cool after autoclaving until it was roughly 
30°C, and antibiotic stocks were added immediately prior to pouring plates to prevent 
decomposition of the antibiotic by the heat. Plates were poured in a laminar flow hood. 
2.2 Gel Electrophoresis  
2.2.1 Horizontal DNA electrophoresis 
1 % agarose gel (1): 50 X TAE (1L): 
500 mg agarose 242 g Tris 
50 mL 1X TAE 57.1 mL glacial acetic acid 
1 μL (0.5 mM) ethidium bromide 50 mM EDTA pH 8.0 
ÆThe gels were visualized with UV light. 
2.2.2 12% Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) 
Solutions for forming the resolving and stacking portion of gels were stored at 4°C. 30% 
acrylamide/bis-acrylamide was filter sterilized and stored in a dark bottle. Solutions for running and 
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visualizing gels were stored at room temperature. Gels were cast and run using the Mini-
PROTEAN 3 cell and casting module (Biorad, Hercules, CA). 
Resolving portion(for 13 gels)  Stacking portion(for 13 gels)  Low range marker:
43.3 mL  bis-acrylamide  7 mL  bis-acrylamide   100 μL  marker 
36.2 mL  H2O    33 mL  H2O    200 μL 5X dye 
27.1 mL  1.5M Tris-HCl pH 8.8 13.8 mL  0.5M Tris-HCl pH 6.8 700 μL water 
1.1 mL  SDS 10%   540 μL  SDS 10%   Heat to 100 °C 
900 μL  APS    433 μL  APS    Aliquot and store 
100 μL  TEMED   54 μL  TEMED    
 
10 X running buffer (1L): Coomassie stain: Destaining solution: 
30 g Tris base 1.25 g Coomassie 50 % ethanol 
144 g glycine Brilliant Blue R-250 10% glacial acetic acid 
10 g SDS 50 % ethanol 
 5 % glacial acetic acid 
The resolving portion of the gel was cast and allowed to solidify before casting the stacking 
portion. Gels were run for 1 h at 150 V in 1X running buffer, diluted from the 10X running buffer 
above. Gels were stained for 15 min in Commassie and destained for several hours. Low range 
molecular weight marker was used as a standard. 
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Sample preparation for SDS-PAGE 
5X Sample buffer: Extraction buffer: 
300 mM Tris 50 mM Tris-HCl (pH 8.0) 
10% (w/v) SDS 1 mM EDTA    
25% β-mercaptoethanol 0.1 M NaCl 
50% glycerol 0.1% Triton X 
  1 mM dithiotheitol (DTT) 
The sample buffer was adjusted to pH 6.8 using 12 N HCl, Bromophenol blue (0.05 %) was 
added, and both sample buffer and extraction buffer were then stored at 4°C.  Immediately prior to 
use, DTT was added to the extraction buffer. 
An aliquot (1 mL) of cells was collected from the culture in a microcentrifuge tube and 
centrifuged for 1 min at 14,000 x g.  Following removal of the supernatant, the pellet was 
resuspended in 250 μL extraction buffer and sonicated on ice (settings:  duty cycle 100%, micro tip 
4, pulsed sonication) for 15 sec. Following sonication, an 80 μL sample was taken (“total”=soluble 
+ insoluble protein), and the solution was centrifuged for 1 min at 14,000 x g. A 80 μL supernatant 
(soluble protein fraction) was then collected in a microcentrifuge tube as well. The total and soluble 
samples were individually mixed with 20 μL 5X sample buffer, vortexed briefly, and heated to 95 °C 
using a heating block for 5 min. 15-20 μL of sample were loaded into each lane of a 12 % SDS-
PAGE gel. 
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2.3 General Procedures 
2.3.1 Protein concentration determination 
Protein concentration was determined using Coomassie reagent (Pierce, Rockford IL) according 
to the Bradford method (1), with a standard curve determined by measuring the visible absorption at 
595 nm of bovine serum albumin (BSA) samples at concentrations of 0.5 mg/mL, 1.0 mg/mL, 1.5 
mg/mL and 2.0 mg/mL at 596 nm. All absorption spectra were recorded using a Shimazdu UV-
2102PC spectrophotometer (Shimadzu, Colombia, MD). 
The protein concentration of the standards and unknowns were determined as follows: a 5 μL 
aliquot of protein was added to 95 μL water and 900 μL of Coomassie reagent in a 1.5 mL 
microcentrifuge tube. The unknown protein was diluted as necessary to obtain a color similar to that 
of the 1.0 mg/mL standard solution. Following 15 min incubation at room temperature, the 
ultraviolet absorption of each sample in a polyethylene cuvette at 595 nm was recorded. The 
spectrophotometer was zeroed against a solution containing only Coomassie reagent (900 μL) and 
water (100 μL). 
2.3.2 DNA concentration determination 
DNA concentration was determined by adding 1 μL of DNA sample to a NanoDrop 
instrument (Thermo Scientific, Wilmington, DE, USA) and measuring absorption at 260 nm. 
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2.3.3 Transformation of  CaCl2 competent cells 
Cells were transformed by adding 1 μL (80 ng) of plasmid DNA to 100 μL of competent cells in 
a pre-chilled 1.5 mL microcentrifuge tube. The mixture was incubated on ice for 30 min, heat 
shocked for 45 sec at 42 °C, and re-incubated on ice for 2 min. 900 μL of LB broth was then added, 
and the mixture was incubated in the shaker at 37°C for 1 hour.  The cells were then centrifuged for 
30 sec at 14,000 x g, and 900 μL of supernatant was removed. The pellet was resuspended in 100 μL 
of the remaining LB broth and plated on LB agar plates containing the appropriate antibiotic(s). The 
plates were incubated overnight at 37°C.   
2.3.4 Preparation of  glycerol stocks 
An 800 μL aliquot of an overnight cell culture was combined with 200 μL of 80% glycerol and 
stored at –80 °C for use in future experiments. 
2.3.5 Plasmid preparation 
Plasmids were collected and purified using the Mini-Prep Kit (Qiagen, Valencia, CA), according 
to the manufacturer’s protocol, with the exception of a final elution volume of 30 μl of water. The 
DNA samples were either used immediately or stored at -20 °C.  
2.3.6 Sequencing 
Amino acid sequences were analyzed by the Microbiology Core at Moffitt Cancer Center. 
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2.3.7 Cold shock induction protocol for expression of  recombinant proteins from E. coli: large 
scale 
This procedure takes advantage of temperature-stressed cells with release of GroEL-GroES 
chaperonins molecules. GroEL belongs to the chaperonin family of molecular chaperones and is 
found in a large number of bacteria. It is required for the proper folding of many proteins. To 
function properly, GroEL requires the lid-like cochaperonin protein complex GroES. Production of 
high levels of chaperonins proteins can also be triggered by exposure to different kinds of 
environmental stress such as temperature, infection, inflammation, and exposure of the cell to toxins 
(ethanol, arsenic, trace metals, and ultraviolet light, among others). They play an important role in 
protein-protein interactions, including folding and assisting in the establishment of proper protein 
conformation (shape) and prevention of unwanted protein aggregation. By helping to stabilize 
partially unfolded proteins, the chaperonins aid in transporting proteins across membranes within 
the cell. 
 
Transformation:  
5-10 ng of DNA was used to transform 50-100 µl of competent cells [following the protocol 
described above in section 2.3.3 in page 19], plating 100-150 µl on LB-agar and the appropriate 
antibiotics. 
 
Growth:   
A single colony of the transformed cells was used to inoculate 300 mL of 2x YT medium 
containing 0.4% glucose with the appropriate antibiotics. Incubate overnight at 37 °C (150-180 rpm 
to ensure that cell density is not too high). 
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Induction: 
Autoclaved flasks containing TB-phosphate medium and appropriate antibiotics were 
allowed to cool to 4 ºC. a) At the end of the growth phase, measure the density at 600 nm (you 
should expect an OD600nm ~1.6-1.8); take 50 µL aliquot (this is your un-induced control).  
b) Harvest the overnight cells culture by centrifugation (10 min, 6 K rpm, 4 °C) and resuspend the 
cell pellet in 100 mL of pre-chilled (4 °C) Terrific Broth-phosphate medium, supplemented with the 
appropriate antibiotics, [This step assures to induce the cells at saturation, taking advantage of 
having the maximum number of cells possible before induction].   
c) Subject the suspended cells to “cold shock” for 30 minutes (incubation in an ice-water bath, while 
keeping the temperature of the bath below 10 °C), [this allows stress of the cells in preparation of 
release of the chaperonin molecules). 
d) At the end of the incubation period, aliquot equally the resuspended cells into the large scale 
flasks (containing TB-phosphate/antibiotics). Add cold 100% Et-OH to make a final concentration 
of 2% in the flasks (release of chaperonins). Induce the cells with 0.1-0.5 mM IPTG at 16-25 °C for 
20 hours (250 rpm), or 44 hours at 10 ºC. 
e) Measure the OD600nm at the end of the expression and withdraw an aliquot (this is your induced 
cells control). 
 
Harvesting:  
Harvest the cells by centrifugation as above and wash with 15 mL/pellet of cold 1x PBS 
(10 min, 6 K rpm, 4 °C).  
 
RECIPES: 
2x YT: 
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1L:  16 g Bacto-Tryptone 
  10 g Yeast Extract 
    5 g NaCl 
Adjust pH to 7.0 with NaOH, adjust volume to 1 L with H2O. Sterilize by autoclaving and store at 
room temperature. 
 
TB-Phosphate 1L 
900 mL:  12 g Bacto-Tryptone 
  24 g Yeast Extract 
  4 mL of 100% glycerol or 8 mL of 50% glycerol (recommended). 
ÆSterilize by autoclaving and cool to < 60 °C. 
ÆAdd 100 mL of sterile 10x TB phosphate* and store at room temperature. 
 
• [10x TB-posphate*: made by dissolving 23.1 g KH2PO4 (= 0.17 M) and 125.4 g K2HPO4 (= 
0.72M) in 900 mL H2O. Adjust volume to 1Lwith H2O and sterilize by autoclaving. Store at 
room temperature]. 
2.4 Protein purification – Fast Protein Liquid Chromatography (FPLC) 
Proteins were prepared for purification by resuspending a cell pellet in extraction buffer (7.5 mL 
buffer / 1.0 g of cells) with lysozyme (1 mg lysozyme / 1 g cells) and stirring for 1 h. The solution 
was sonicated (settings: duty cycle 7, pulsed sonication) on ice for 2 x 30 sec. After sonication, the 
solution was homogenized at 12,000 psi and 4°C. Following this cell lysis phase, the solution was 
centrifuged for 30 min at 14,000 rpm and a sample was taken. 
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The supernatant following centrifugation was purified at 4 °C using an ÄKTA FPLC system 
(Amersham Biosciences, Piscataway, NJ). The first purification step utilized a Nickel-nitriloacetic 
acid (NiNTA) column (affinity chromatography), which was equilibrated using Buffer A – NiNTA 
#1. After washing with 8 column volumes (CV) of Buffer A, unspecifically bound impurities were 
eluted by 3 CV of 30% Buffer B – NiNTA #1 (containing a small amount of imidazole), then the 
protein was eluted with 3 CV of 100% Buffer B – NiNTA #1 (higher imidazole content). Fractions 
were analyzed for protein presence using SDS-PAGE. Those containing target protein were 
combined and concentrated using an Amicon device (Fisher Scientific, Chicago, IL) with a 30 kD 
filter (Millipore, Bedford, MA) and desalted with Desalting Buffer #1 using a Sephadex column.  
The sample was then cleaved overnight (~16 h) with PreScission protease in a 20:1 (MBP-LDH-
A : PreScission) ratio. This cleaved protein solution was then concentrated to 2 mg/mL using the 
same Amicon and desalted into Buffer A – NiNTA #2 using the same Sephadex column. Fractions 
containing protein were then pooled and concentrated to 3 mg/mL. This protein was subjected to a 
second NiNTA purification, equilibrated with Buffer A – NiNTA #2. Protein was eluted by 
increasing the imidazole concentration in the mobile phase over 1 CV via a gradient from 0-100% 
Buffer B – NiNTA #2. Following SDS-PAGE analysis, fractions containing the protein were 
pooled, concentrated, and desalted into Buffer A – Q-Sepharose. This sample was then loaded on a 
Q-Sepharose (anion exchange) column (CV=5 mL), and the protein was eluted by increasing the salt 
concentration via a gradient from 0-100% Buffer B – Q-Sepharose. Fractions containing protein 
were pooled, concentrated to 5 mg/ mL, and loaded onto a Sephadex 200 column that had been 
equilibrated with gel filtration buffer. After this column, protein samples were concentrated to 
7 mg/mL and stored in 2 mL aliquots at –80 °C after shock freezing with liquid N2.  
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PD-10 desalting columns (Amersham Biosciences) were used to desalt the protein in preparation 
for crystallization. The columns were equilibrated with crystallization buffer, and a 2.5 mL aliquot of 
protein was loaded onto the column and eluted with 3.5 mL of the crystallization buffer according 
to the manufacturer’s protocol. The columns were re-equilibrated with 15 – 25 mL of buffer prior to 
re-use if more protein was to be purified. The eluted protein was concentrated with Centricon 
devices with a 30 kD cutoff (Millipore, Bedford, MA). Approximately 2 mL of protein was added to 
the Centricon device and centrifuged for 25 min at 4,000 rpm and 4 °C. Flow-though was discarded, 
and the device was refilled and centrifuged for 25 min repeatedly until all the protein had been 
added to the device, at which point it was centrifuged for to concentrate the sample. 
2.5 Crystallization 
Prior to crystallization, NADH was added, and the protein sample was diluted to 15 mg/ mL.  
The protein was then crystallized via vapor-diffusion method as a 1:1 sitting drop crystal screen with 
buffers from Index (Hampton Research, Laguna Niguel, CA). Wells that showed promising 
conditions were optimized using a VDX 24 well plate (Hampton Research) and a 22 mm siliconized 
glass coverslide (Hampton Research) for hanging-drop vapor-diffusion method.  
2.6 Enzyme kinetics of  LDH-A 
The enzymatic activity of LDH-A was measured in a 1 mL reaction with 0.25 μg/mL LDH-A (7 
nM), 200 µM NADH and varying concentrations of pyruvate from 12.5-120 µM. A 50 mM 
phosphate buffer (pH 6.5) was used. A table corresponding to the setup of these reactions is 
included below (Table 2-2), and the final concentrations for the changing variable (pyruvate) are 
listed in Table 2-1 A. After determining the Km of pyruvate to be 129.6 µM, this concentration was 
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used when performing experiments to find the IC50 value for oxamate, a weak inhibitor. Table 2-3 
details the kinetics experiments performed to find the IC50 of oxamate, while Table 2-1 B shows the 
final concentrations of the changing parameter (oxamate) of this experiment.  
Table 2-1. Final concentrations in the reactions for Km measurement and IC50 measurement. 
Assay 
number 
A. Pyruvate concentration (µM) 
in pyruvate Km measurement 
B. Oxamate concentration (µM)
in oxamate IC50 measurement 
1 12.5 0.39 
2 25 1.56 
3 50 3.125 
4 100 6.25 
5 150 12.5 
6 200 25.0 
7 300 50.0 
8 400 100.0 
9 600 200.0 
10 800 400.0 
11 1200 500.0 
12  600.0 
13  800.0 
14  1000.0 
15  1200.0 
 
 
 
 
 
 
 
 
 
 
 
25 
 
Table 2-2. Pipetting protocol and portions for measuring activity of LDH-A. 
Assay 
number: 
Quantity 
(μL) of 20 
mM NADH 
Concentration 
of pyruvate 
(mM; 
changing 
variable) 
Quantity of 
Buffer (μL) 
Quantity of 
0.025 mM 
LDH-A (μL)  
Total 
reaction 
1-11 10 μL 1.25-120 970 μL 10 μL 1 mL 
 
Table 2-3. Pipetting protocol and portions for measuring of IC50 of LDH-A using oxamate. 
Assay 
Number 
Quantity of 
Buffer (μL) 
Quantity 
(μL) of 12.96 
µM Pyruvate
Quantity 
(μL) of 20 
mM NADH
Concentration 
of Oxamate 
(nM; changing 
variable) 
Concentratio
n of Inhibitor 
(nM) 
1-15 960 10 10 3.9-120 10 
 
Absorbance was measured at 340 nm using a UV-1650PC UV-Vis spectrophotometer from 
Shimadzu (Columbia, MD, USA). 
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3 RESULTS 
3.1 Lactate Dehydrogenase Subcloning #1 
The ldha gene was purchased from GENEART (Regensburg, Germany) in a pGA4 (ampicillin-
resistant) cloning vector backbone (Figure 3-1). The gene was amplified using E. coli DH5α cells, and 
the DNA was isolated using a Qiaprep Miniprep kit (Qiagen, [location?]). The sample concentration 
was then measured using a NanoDrop (Thermo Scientific,Wilmington, Delaware). LDH-A was 
subcloned into three vectors with different tags: MBP-pET28a (an in-house modified pET28a 
vector with MBP tag), pET28a-PreScission, and pGEX-6P-1. The gel showed that the digestion 
reactions went to completion (Figure 3-2), which was confirmed by DNA sequencing performed by 
the Moffitt Cancer Center’s molecular biology core facility. 
 
Figure 3-1. GENEART LDH-A in pGA4 DNA construct. This is the vector map 
supplied by GENEART illustrating the pGA4 plasmid containing the ldha gene optimized for 
expression in E. coli. 
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 Figure 3-2. LDH-A-pGA4, MBP-pET28a, pET28a-PreScission, and pGEX-6P-1 digestion 
reaction gel. The gel shows a complete digestion reaction for all samples. 
3.2 Overexpression studies 
After ligation of LDH-A into MBP-pET28a, pET28a-PreScission (His6), and pGEX-6P-1 
expression vectors, overexpression studies were performed to find suitable conditions for soluble 
LDH-A. LDH-A in the MBP-pET28a vector, which includes a His6 tag, was transformed into 
Tuner(DE3) E. coli cells, and overexpression studies at 37°C and 16°C were attempted, using 
0.5 mM IPTG to induce expression. (Figure 3-3 and Figure 3-4). 
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Figure 3-3. LDH-A- MBP at 37°C with 0.5mM IPTG. Lane 1: marker; Lane 2: control 
(before induction with IPTG), total lysate; Lane 3: control, soluble lysate; Lane 4: induced sample 
after 3 h of protein growth, total lysate; Lane 5: induced sample, soluble lysate. A second clone was 
induced to provide a second control and is shown in lanes 6 and 7 as total and soluble protein, 
respectively. The control lanes show bands corresponding to Negative controls show LDHA, so the 
cell is leaky and there is a very small amount of soluble LDH-A can be obtained. 
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Figure 3-4. LDH-A- MBP at 16°C with 0.5 mM IPTG. The lanes for this gel correspond to 
those in Figure 3-3, except that these samples were induced and grown at 16°C. Again, leakage and 
poor solubility are observed.  
Following these results, LDH-A overexpression studies were set up using the cold shock 
method. Results are shown in Figure 3-5. 
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Figure 3-5. LDH-A- MBP overexpression using cold shock method with 0.5mM IPTG. 
Lane 1: marker; Lane 2 and lane 3: are the controls; Lane 4 and lane 5 cold shock induced samples 
grown overnight. The cells are slightly leaky, suggesting that the protocol can be optimized. 
Protein overexpression studies were next performed using the LDH-A-pGEX-6P-1 construct, 
containing a GST-tag, in E. coli Tuner (DE3) cells. Results are shown in Figures 3-6 and 3-7. 
 
MW      1          2          3           4 
31 
 
 Figure 3-6. GST-LDH-A overexpression using various concentrations of IPTG. 
C=control, T=total, S=soluble. Cells did not show leakage but exhibited overexpression. However, 
the protein did not appear to be soluble. 
 
 
Figure 3-7. GST-LDH-A overexpression using various IPTG concentrations. Lower 
IPTG concentrations were used in order to see if soluble protein would be overexpressed. No 
solubility was observed. 
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Next, protein overexpression studies were performed using the LDH-A-pET28a (His6-tag) 
vector in E. coli BL21(DE3) and E. coli BL21(DE3) pLysS cells by inducing with 0.5 mM IPTG and 
growing at 37°C and 16°C. Results are shown in Figure 3-8.  
 
Figure 3-8. His6- LDH-A overexpression using 0.5mM IPTG at 37°C and 16°C. The 
labeled gel shows the cells are either leaky without soluble protein, or just without soluble protein. 
Expression studies were then carried out using cold shock induction with various IPTG 
concentrations in both BL21 (DE3) and BL21 (DE3) pLysS cells. Results are shown in Figure 3-9 
and Figure 3-10, although no promising results were found. 
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 Figure 3-9. His6 - LDH-A overexpression in BL21(DE3) by cold shock induction studies 
using 0, 0.1, and 0.5 mM IPTG. All cells show leakage despite the variations in IPTG and 
overexpression.  
 
Figure 3-10. His6 - LDH-A overexpression in BL21(DE3) pLysS by Cold Shock induction 
studies using 0, 0.1, and 0.5 mM IPTG. This cell strain also shows leakage at all IPTG 
concentrations. 
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In summary, the only promising results found were using the LDH-A-MBP overexpression 
using a modified cold shock method with 0.5 mM IPTG, so the subcloning was repeated to ensure 
that the protocol was reproducible and to confirm and optimize the expression.  
3.3 Subcloning #2 
Agarose gel results for the digestion reaction of the repeat subcloning are shown in Figure 3-11, 
with the final recombinant DNA construct shown in Figure 3-12. After ligation, the sequence was 
verified by the Moffitt Cancer Center Molecular Biology core facility. 
 
Figure 3-11. LDH-A and MBP-pET28a DNA preparations. A) LDH-A plasmid DNA; B 
and C) LDH-A digested with BamHI and NotI restriction enzymes; D) 1 kbp DNA marker; E and 
F) MBP-pET28a vector digested with BamHI and NotI; G) undigested MBP-pET28a plasmid 
(control).  
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 Figure 3-12. Recombinant LDH-A DNA construct with MBP. This is a map of the DNA 
construct used to produce His6-MBP-LDH-A.  
3.4 Large scale protein overexpression 
After comparing the results from multiple induction studies, LDH-A in fusion with MBP-His6 in 
the pET28a vector and E. Coli Tuner (DE3) cells was chosen for large scale production of LDH-A. 
Unfortunately, Although, when scaling the LDH-A over expression from a small scale to a large 
scale using the cold shock method, the protocol did not appear to work, and LDH-A was not 
expressed. The protocol was then further modified by scaling up the overnight starting culture (in 2 
xYT) to a large scale, as opposed to the regular protocol using which a small scale of 2 xYT is grown 
overnight and cold shocked, then inoculating in a large scale[4 L] of TB medium. The product, as 
analyzed by SDS-PAGE analysis, is shown in Figure 3-13.  
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Figure 3-13. Large scale overexpression of LDH-A. First lane shows the marker. Second and 
third lane show the total and supernatant protein prior to induction. The fourth and fifth lane are 
total and soluble LDH-A over expressed with 0.25mM IPTG using the cold shock procedure. The 
gel shows highly overexpressed and soluble LDH-A, so the protocol was deemed appropriate to 
proceed to the next step.  
3.5 Protein purification – Fast Protein Liquid Chromatography (FPLC) 
LDH-A was purified as described in section 2.4, following the purification steps summarized in 
Figure 3-14. 
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 Figure 3-14. Flow chart of protein purification. The major steps of the purification are 
shown, skipping omitting the desalting steps. 
 
 The resulting FPLC elution profile and SDS-PAGE gel from the first NiNTA column is shown 
as Figure 3-15; the second NiNTA column in Figure 3-16; the Q-Sepharose column in Figure 3-17; 
and the Superdex 200 column in Figure 3-18. 
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Figure 3-15. Elution profile of NiNTA column #1. Gel shows that the first peak is a mixture 
of LDH-A and other impurities, while the second peak contains a high concentration of our target 
protein (LDH-A). 
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 Figure 3-16. Elution profile of NiNTA column #2. Flowthrough fractions contain a mixture 
of the cleaved maltose-binding protein tag and untagged LDH-A, while the elution peak shows fairly 
pure LDH-A with a small quantity of free MBP tag. 
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 Figure 3-17. Elution profile of Q Sepharose column. The elution profile and gel confirm that 
most of the protein comes out with the peak. 
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 Figure 3-18. Elution profile of Superdex 200 column. The elution profile shows where the 
quaternary LDH-A protein is eluted using a gel filtration column. 
 
A summary gel of the purification in Figure 3-19, with the corresponding protein content 
tracking table listed as Table 3-1.  
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 Figure 3-19. LDH-A purification overview. Molecular weight marker, crude sample, sample 
after the first NiNTA column, overnight cleavage reaction result, sample after the second NiNTA, 
sample after Q Sepharose column (anion exchange), and pure LDH-A protein sample after 
Superdex 200 column (size exclusion). 
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Table 3-1.  Summary of protein content. Protein concentrations and quantities as determined 
throughout the multiple purification steps. 
   His‐MBP‐LDH‐A purification  
Protein 
Concentration  Volume
Total 
Protein   % YIELD 
      (mg/mL)  (mL)  (mg)    
1  Cell Pellet  ‐     40g    
2 
Crude Extract (Cell Lysis 
Supernatant)  14.400  170.0  2448.0  100.0 
3  NiNTA Pool  0.449  190.0  85.3  3.5 
4  NiNTA Pool concentrated  1.195  70.0  83.7  3.4 
5  LDH‐A pre‐cleavage reaction  0.53  150.0  79.5  3.4 
6  LDH‐A post‐cleavage reaction  0.520  150.0  78.0  3.2 
7 
LDH‐A post‐cleavage reaction 
concetrated  2.000  39.0  78.0  3.2 
8  Desalted for NiNTA2 (8mL)  0.707  108.0  76.4  3.1 
9 
Desalted for NiNTA2 (8mL) 
concentrated  3.208  23.0  73.8  3.0 
10  NiNTA 2 pool  1.027  70.00  71.9  2.9 
11  Q Sepharose load  16.000  2.00  32.0  1.3 
12  Superdex 200 pool  0.201  50.00  10.1  0.4 
13  Superdex 200 pool concentrated  5  2  10  0.4 
 
3.6 Protein Crystallization 
LDH-A was desalted into 50 mM Tris a of pH 7.0 using a PD-10 desalting column, and was 
concentrated to 14 mg/ mL using Centricon. In order to find crystallization conditions for LDH-A 
complexed with NADH bound, the Index crystal screen (Hampton Research, CA) was used. Each 
droplet contained 1 μL protein and 1 μL crystal screen solution.  Plates were incubated at 19 °C and 
checked at intervals of 1, 2, and 4 days, and 1, 2, and 4 weeks. Crystals formed within the first two 
days of incubation and continued to grow slightly as time passed. The conditions in which good 
crystal growth was observed contained 0.1 M magnesium formate dihydrate with 15% PEG, as 
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shown in Figure 3-20, or 0.1 M succinic acid pH 7.0 and 15% PEG. The succinic acid condition was 
f using the hanging drop method; results are shown in Figure 3-21. 
 
Figure 3-20. Crystals in 0.1 M magnesium formate dihydrate with 15% PEG. 
 
Figure 3-21. Crystals in 0.1 M succinic acid pH 7.0 and 15% PEG. 
0.5 mm
0.5 mm
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3.7 Enzyme kinetics of  LDH-A 
Steady-state kinetic characterization revealed Km (Pyruvate) to be 130 ± 19 µM and the specific 
activity to be 382 ± 16 U/mg, as shown in Figure 3-22. The IC50 value for the weak inhibitor 
oxamate was determined to be 65 ± 2 µM, shown in Figure 3-23. The literature value for Km (pyruvate) 
is 158 µM, and IC 50 of oxamate is 26 µM (3). These values match very well with measured values. 
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Figure 3-22. Graph used to determine values for Vmax and Km(pyruvate). The data points were 
fit into the Michaelis-Menten Equation. 
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Figure 3-23. IC50 of oxamate and the variation between data points. The data points were 
fit into:   
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4 DISCUSSION  
Despite being one of the most studied enzymes and a model enzyme for explanation of 
biochemistry concepts, much remains to be known about altering the activity of lactate 
dehydrogenase for clinical purposes. As a part of this thesis project, the ldha gene was subcloned 
into a vector, transformed into bacterial cells, overexpressed, purified, crystallized, and biochemically 
characterized. This process required a large amount of effort as conditions needed to be found and 
optimized at each step of the process.  
4.1 Subcloning and overexpression studies 
The ldha gene was subcloned into MBP-pET28a, pET28a-PreScission, and pGEX-6P-1. MBP-
pET28a was the first to be transformed into E. Coli Tuner (DE3) cells. Overexpression studies were 
performed, as shown in Figures 3-2, 3-3, and 3-5, and overexpression of LDH-A was observed. 
However, only cold shock induction showed results that were promising enough to continue, with 
protein only overexpressed in samples that were induced with IPTG. One of the ways to reduce 
leakiness is to grow the cell culture at a lower temperature but using cold shock induction the 
temperature is as low as it can be, and these are the only suitable conditions found. 
Other conditions were tried as well, including the pGEX-6P-1 vector in E. coli Tuner (DE3) cells 
with different IPTG concentrations and growth conditions shown in Figure 3-6 and Figure 3-7, but 
leakiness was observed and no soluble LDH-A was obtained. Poor results were also obtained when 
using the pET28a-PreScission vector with BL21 (DE3) and BL21 (DE3) pLysS cells, as shown in 
Figures 3-8, 3-9, and 3-10. 
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4.2 Large scale protein overexpression 
As the only promising conditions appeared to be the LDH-A-MBP-pET28a construct in E. coli 
Tuner (DE3) using cold shock induction with 0.5 mM IPTG, subcloning was repeated. The same 
results were shown for overexpression, so this was scaled up to a large scale LDH-A cell culture. 
However, corresponding levels of overexpression were not observed, and SDS-PAGE analysis 
showed only a very small amount of protein in the soluble portion.  
When doing overexpression with cold shock induction, a 50 mL culture of cells in 2xYT media 
are cold shocked, and all of the cells are resuspended in 50 mL of TB media. All cells that have been 
cold shocked have chaperone proteins induced by the cold shock, which helps them produce soluble 
LDH-A. However, when overexpressing a protein on a large scale using cold shock induction, six 
flasks of 50 mL 2x YT overnight culture are grown, cold shocked, and aliqouted into 6 flasks with 
660 mL TB media to be induced in. I concluded that, as not all cells were cold shocked and allowed 
to focus solely on overexpression, this standard large scale cold shock protocol was not effective for 
LDH-A production. 
Cold shock induction for a large scale was therefore modified to match the growth conditions of 
the expression studies. The overnight culture in E. coli Tuner (DE3) cells in 2x YT media was scaled 
up to 6 flasks of 660 mL each, and each portion was cold shocked and aliquoted in 660 mL of TB 
media. After all the cells in the TB media were cold shocked and the starting OD600 was 
approximately 3, all of the cells should be able to focus on overexpression instead of growth. The 
OD600 at harvest was approximately 5, and SDS-PAGE analysis showed good overexpression and 
solubility. The protocol was shown to be reproducible in growing cell pellets for subsequent 
purification.  
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4.3 Protein purification – fast protein liquid chromatography (FPLC) 
LDH-A was purified as in section 2.4, but the protocol required modifications to three earlier 
purification protocols as certain buffer conditions and columns proved ineffective in the process. 
The purification protocol that was used is summarized in Figure 3-14. 
The purification was started with a nickel-nitriloacetic acid (NiNTA) affinity column which 
binds imidazole residues, making it the perfect affinity column for a protein tagged with six histidine 
residues. After loading the crude cell lysate, His6-LDH-A-MBP fusion protein was eluted in a two 
step gradient with 30% NiNTA1 Buffer B in the first step and 100% NiNTA1 Buffer B in the 
second step of the gradient. As shown in Figure 3-15, the flowthrough did not contain any of the 
desired protein, the proteins from the first step of the gradient were impurities with a small amount 
of LDH-A which apparently did not bind tightly to the column, and the eluate from the second step 
gradient was fairly pure LDH-A. 
After the first NiNTA column, the protein was cleaved with PreScission enzyme to yield His6-
LDH-A and MBP-tag, and the two proteins were separated using a second NiNTA column. The 
elution profile and SDS-PAGE gel are shown in Figure 3-16. The flowthrough shows a mixture of 
LDH-A and MBP that does not bind to the column. As it was assumed that LDH-A should bind 
and this portion did not, it was thought to be improperly folded LDH-A. The eluate peak shows 
that the earlier tubes contain pure LDH-A, while the later fractions contain MBP. This tells us that 
there is some unspecific binding between the two proteins, and more purification steps are required. 
The pool from the second NiNTA column was desalted, concentrated, and loaded into a Q-
Sepharose column. This column is an anion exchage column, meaning it will bind negatively charged 
proteins, and elute . The pI of His6-LDH-A is 5.24, while the pI of MBP is 8.46, therefore, the 
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buffer pH was set at 7.5 in order to result in negatively charged LDH-A and neutral MBP. The 
elution profile for this step is shown in Figure 3-17, showing that MBP is in the flowthrough, along 
with a small amount of uncharged LDH-A [??]. The elution portion, however, shows a very clean 
LDH-A portion that was pooled, concentrated, and loaded into a gel filtration column. 
The elution profile from the Superdex 200 gel filtration column is shown in Figure 3-18 and 
shows a single peak with no aggregated LDH-A. Since the size of the LDH-A tetramer is 
approximately 144 kD, the sample eluted out at the corresponding 204 mL, as expected. The 
fractions were pooled, concetrated, frozen and stored at -80 °C. The LDH-A purification overview 
gel can be seen in Figure 3-19, and a purification table is shown as well (Table 3-1). 
4.4 Protein Crystallization 
The crystallization process was fairly straightforward, and only training on how to set up the 
robot was required. The Index screen from Hampton Research was used in order to screen for 
crystallization conditions, and the protein concentration was set at 14 mg/ mL; slightly less than the 
standard Schönbrunn lab protocol because very little protein was available from the purification. 
After the conditions with the most promising crystals were found, they were further optimized by 
using the same buffer conditions in a 1:1 hanging drop plate. This method normally results in larger 
crystals with better growth? The resulting crystals are shown in Figure 3-15. These crystrals will be 
measured in the future, and the molecular structure will be solved using molecular modeling. 
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4.5 Enzyme kinetics of  LDH-A 
Steady-state kinetic experiments were performed to elucidate the activity of the purified protein. 
After determining the specific activity, the affinity (Km) of pyruvate for LDH-A was derived. Using 
this information, the pyruvate concentration was maintained at a constant level to elucidate the IC50 
value of oxamate, a known weak inhibitor of LDH-A.  The literature value for Km (pyruvate) is 158 µM, 
which is a relatively small deviation from the measured value of 126 µM. The liturature IC50 of 
oxamate is 26 µM, which also does not vary much from our measured value of 64.8 µM. This shows 
that the protein that was used is close to optimal shape. 
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5 CONCLUSION 
The overexpression and purification of LDH-A are highly reproducible and provide a solid 
basis for drug discovery methodology with this protein. Future plans include high-throughput 
screening (HTS) for novel LDH-A inhibitors, co-crystallization of LDH-A with HTS hit 
compounds, and structure-based design of potent and specific lead inhibitors of this enzyme. 
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